EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.
Yamaguchi H, et al. Among authors: chang ss, chang wc.
Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.
Oncogene. 2018.
PMID: 28925391
Free PMC article.